Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29583255 | 1.00 | KMT2A (0.57) | KMT2AMEN1AHRPRNPLMNA | |
| SCHEMBL869550 | 0.89 | BRD4 (0.50) | KMT2AMEN1AHRLMNATSHR | |
| SCHEMBL70429 | 0.88 | LMNA (0.59) | KMT2AMEN1LMNATSHRALDH1A1 | |
| SCHEMBL25523280 | 0.86 | SLC6A3 (0.56) | KMT2AMEN1AHRPRNPLMNA | |
| SCHEMBL30848483 | 0.85 | PRNP (0.56) | KMT2AMEN1AHRPRNPALDH1A1 | |
| SCHEMBL4959202 | 0.85 | PRNP (0.56) | KMT2AMEN1AHRPRNPALDH1A1 | |
| SCHEMBL31525357 | 0.82 | KMT2A (0.45) | KMT2AMEN1AHRPRNPLMNA | |
| SCHEMBL29279663 | 0.81 | TSHR (0.52) | KMT2AMEN1LMNATSHRALDH1A1 | |
| SCHEMBL3230050 | 0.81 | NR4A2 (0.53) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL28485658 | 0.81 | KMT2A (0.61) | KMT2AMEN1AHRPRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4565121-A1 | CARBON MONOXIDE PROBE MOLECULES | Georgia State University Research Foundation, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119997870-A | Carbon monoxide probe molecule | 乔治亚州立大学研究基金会股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024030944-A1 | CARBON MONOXIDE PROBE MOLECULES | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-6495710-B2 | Synthesis and use of dimethyl 1,5-naphthalenedicarboxlyates and intermediates therefrom | BP CORPORATION NORTH AMERICA INC. | 2002-12-17 | — | — | US | disclosed |
| US-20010031852-A1 | Synthesis and use of dimethyl 1,5-naphthalenedicarboxylates and intermediates therefrom | BP CORPORATION NORTH AMERICA INC. | 2001-10-18 | — | — | US | disclosed |
| EP-1140823-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001051450-A2 | SYNTHESIS AND USE OF DIMETHYL-1,5-NAPHTHALENEDICARBOXYLATES AND INTERMEDIATES THEREFROM | BP CORPORATION NORTH AMERICA INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6166034-A | Spiro piperidine derivatives as 5HT1D receptor antagonists | SMITHKLINE BEECHAM P. L. C (GB) | 2000-12-26 | — | — | US | disclosed |
| WO-2000039088-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-06 | — | — | WO | disclosed |
| EP-0861257-A1 | SPIRO PIPERIDINE DERIVATIVES AS 5MT RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997017351-A1 | SPIRO PIPERIDINE DERIVATIVES AS 5MT RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-05-15 | — | — | WO | disclosed |
| US-5183825-A | Antidiabetic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | KMT2A 1072/4885MEN1 772/4885AHR 3258/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | KMT2A 824/4885MEN1 3549/4885AHR 752/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | KMT2A 663/4885MEN1 859/4885AHR 2566/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | KMT2A 670/4885MEN1 2979/4885AHR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.